A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Sponsor
Purdue Pharma LP (Industry)
Overall Status
Completed
CT.gov ID
NCT01427283
Collaborator
(none)
450
150
3
38
3
0.1

Study Details

Study Description

Brief Summary

The primary objective is to assess the efficacy of oxycodone/naloxone controlled-release tablets (OXN) for the management of opioid-induced constipation (OIC) compared with oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low back pain and opioid-induced constipation who require around-the-clock opioid therapy.

Condition or Disease Intervention/Treatment Phase
  • Drug: Oxycodone/Naloxone controlled-release
  • Drug: Oxycodone HCl controlled-release
  • Drug: Placebo
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
450 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy
Study Start Date :
Aug 1, 2011
Actual Primary Completion Date :
Oct 1, 2014
Actual Study Completion Date :
Oct 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: OXN

Oxycodone/Naloxone controlled-release tablets (OXN)

Drug: Oxycodone/Naloxone controlled-release
Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours

Active Comparator: OXY

Oxycodone HCl controlled-release tablets (OXY)

Drug: Oxycodone HCl controlled-release
Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
Other Names:
  • OxyContin
  • Placebo Comparator: Placebo

    Placebo tablets to match OXN or OXY

    Drug: Placebo
    Placebo tablets to match OXN or OXY taken orally every 12 hours

    Outcome Measures

    Primary Outcome Measures

    1. Overall complete spontaneous bowel movement (CSBM) responder rates [Weeks 1 through 12]

      The overall Complete Spontaneous Bowel Movement (CSBM) responder rates over the 12 week double-blind period comparing OXN to OXY

    Secondary Outcome Measures

    1. CSBM Responder at least 50% of the weeks in the double-blind period [Weeks 1 through 12]

    2. Laxative-free Responder at least 50% of the weeks in the double-blind period [Weeks 1 through 12]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria include:
    • Male and female subjects ≥ 18 years of age with moderate to severe, chronic low back pain (lasting at least several hours daily) as their predominant pain condition for at least 3 months prior to screening period;

    • The low back pain must be related to nonmalignant and nonneuropathic conditions and may be with or without radiation;

    • Subjects must have a self-reported history of opioid induced constipation (OIC).

    Exclusion Criteria include:
    • Subjects with rheumatoid arthritis or other inflammatory arthritis;

    • Subjects with neuropathic conditions that have been painful or required therapy within the past 3 months;

    • Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract or other significant conditions affecting GI motility;

    • Subjects with chronic constipation not related to opioid use;

    • Subjects who had surgical procedures directed towards the source of chronic low back pain within 6 months of the screening visit or planned during the study;

    • Subjects with a history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated.

    Other protocol specific inclusion/exclusion criteria may apply.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Investigational Site Alabaster Alabama United States 35007
    2 Investigational Site Birmingham Alabama United States 35213
    3 Investigational Site Birmingham Alabama United States 35216
    4 Investigational Site Foley Alabama United States 36535
    5 Investigational Site Mobile Alabama United States 36608
    6 Investigational Site Mesa Arizona United States 85202
    7 Investigational Site Phoenix Arizona United States 85020
    8 Investigational Site Phoenix Arizona United States 85021
    9 Investigational Site Sun Lakes Arizona United States 85248
    10 Investigational Site Tucson Arizona United States 85704
    11 Investigational Site Tucson Arizona United States 85712
    12 Investigational Site Little Rock Arkansas United States 72211
    13 Investigational Site Sherwood Arkansas United States 72120
    14 Investigational Site Anaheim California United States 92801
    15 Investigational Site Anaheim California United States 92804
    16 Investigational Site Artesia California United States 90701
    17 Investigational Site Cerritos California United States 90703
    18 Investigational Site Chino California United States 91710
    19 Investigational Site El Cajon California United States 92020
    20 Investigational Site Encino California United States 91436
    21 Investigational Site Fountain Valley California United States 92708
    22 Investigational Site Fresno California United States 93720
    23 Investigational Site Garden Grove California United States 92843
    24 Investigational Site Garden Grove California United States 92844
    25 Investigational Site Laguna Hills California United States 92653
    26 Investigational Site Lakewood California United States 90712
    27 Investigational Site Lincoln California United States 95648
    28 Investigational Site Lomita California United States 90717
    29 Investigational Site Long Beach California United States 90806
    30 Investigational Site Oceanside California United States 92054
    31 Investigational Site Orange California United States 92868
    32 Investigational Site Paramount California United States 90723
    33 Investigational Site Sacramento California United States 95823
    34 Investigational Site San Bernardino California United States 92408
    35 Investigational Site San Diego California United States 92103
    36 Investigational Site San Diego California United States 92114
    37 Investigational Site Thousand Oaks California United States 91360
    38 Investigational Site Torrance California United States 90509
    39 Investigational Site Colorado Springs Colorado United States 80907
    40 Investigational Site Colorado Springs Colorado United States 80909
    41 Investigational Site Denver Colorado United States 80246
    42 Investigational Site Golden Colorado United States 80401
    43 Investigational Site Aventura Florida United States 33180
    44 Investigational Site Bradenton Florida United States 34209
    45 Investigational Site Chiefland Florida United States 32626
    46 Investigational Site Clermont Florida United States 34711
    47 Investigational Site Daytona Beach Florida United States 32117
    48 Investigational Site Deland Florida United States 32720
    49 Investigational Site Edgewater Florida United States 32132
    50 Investigational Site Ft. Lauderdale Florida United States 33316
    51 Investigational Site Ft. Myers Florida United States 33916
    52 Investigational Site Hialeah Florida United States 33010
    53 Investigational Site Hialeah Florida United States 33012
    54 Investigational Site Inverness Florida United States 34452
    55 Investigational Site Jacksonville Florida United States 32216
    56 Investigational Site Jacksonville Florida United States 32256
    57 Investigational Site Jacksonville Florida United States 32257
    58 Investigational Site Miami Beach Florida United States 33140
    59 Investigational Site Miami Florida United States 33015
    60 Investigational Site Miami Florida United States 33125
    61 Investigational Site Miami Florida United States 33126
    62 Investigational Site Miami Florida United States 33135
    63 Investigational Site Miami Florida United States 33136
    64 Investigational Site Miami Florida United States 33144
    65 Investigational Site Miami Florida United States 33145
    66 Investigational Site Miami Florida United States 33155
    67 Investigational Site Miami Florida United States 33165
    68 Investigational Site Miami Florida United States 33185
    69 Investigational Site Naples Florida United States 34110
    70 Investigational Site Naples Florida United States 34113
    71 Investigational Site New Smyrna Beach Florida United States 32168
    72 Investigational Site North Miami Florida United States 33161
    73 Investigational Site Oldsmar Florida United States 34677
    74 Investigational Site Orlando Florida United States 32806
    75 Investigational Site Oviedo Florida United States 32765
    76 Investigational Site Plantation Florida United States 33317
    77 Investigational Site Tamarac Florida United States 33321
    78 Investigational Site Tampa Florida United States 33607
    79 Investigational Site West Palm Beach Florida United States 33409
    80 Investigational Site Atlanta Georgia United States 30308
    81 Investigational Site Austell Georgia United States 30106
    82 Investigational Site Snellville Georgia United States 30078
    83 Investigational Site Boise Idaho United States 83704
    84 Investigational Site Boise Idaho United States 83713
    85 Investigational Site Chicago Illinois United States 60616
    86 Investigational Site Chicago Illinois United States 60622
    87 Investigational Site Chicago Illinois United States 60657
    88 Investigational Site Evansville Indiana United States 47714
    89 Investigational Site Indianapolis Indiana United States 46250
    90 Investigational Site Michigan City Indiana United States 46360
    91 Investigational Site Wichita Kansas United States 67203
    92 Investigational Site Edgewood Kentucky United States 41017
    93 Investigational Site Lake Charles Louisiana United States 70601
    94 Investigational Site Monroe Louisiana United States 71201
    95 Investigational Site New Orleans Louisiana United States 70119
    96 Investigational Site Pikesville Maryland United States 21208
    97 Investigational Site Brockton Massachusetts United States 02301
    98 Investigational Site Worcester Massachusetts United States 01605
    99 Investigational Site Florissant Missouri United States 63031
    100 Investigational Site Las Vegas Nevada United States 89119
    101 Investigational Site Atco New Jersey United States 08004
    102 Investigational Site Great Neck New York United States 11023
    103 Investigational Site Kew Gardens New York United States 11415
    104 Investigational Site New York New York United States 10023
    105 Investigational Site Rochester New York United States 14618
    106 Investigational Site Williamsville New York United States 14221
    107 Investigational Site Durham North Carolina United States 27710
    108 Investigational Site Elkin North Carolina United States 28621
    109 Investigational Site High Point North Carolina United States 27262
    110 Investigational Site Winston Salem North Carolina United States 27103
    111 Investigational Site Winston-Salem North Carolina United States 27103
    112 Investigational Site Columbus Ohio United States 43213
    113 Investigational Site Dayton Ohio United States 45406
    114 Investigational Site Moraine Ohio United States 45439
    115 Investigational Site Toledo Ohio United States 43614
    116 Investigational Site Oklahoma City Oklahoma United States 73103
    117 Investigational Site Oklahoma City Oklahoma United States 73109
    118 Investigational Site Oklahoma City Oklahoma United States 73119
    119 Investigational Site Eugene Oregon United States 97404
    120 Investigational Site Jenkintown Pennsylvania United States 19046
    121 Investigational Site Levittown Pennsylvania United States 19056
    122 Investigational Site Mechanicsburg Pennsylvania United States 17055
    123 Investigational Site Pittsburgh Pennsylvania United States 15215
    124 Investigational Site Red Lion Pennsylvania United States 17356
    125 Investigational Site State College Pennsylvania United States 16801
    126 Investigational Site Warwick Rhode Island United States 02886
    127 Investigational Site Charleston South Carolina United States 29406
    128 Investigational Site Myrtle Beach South Carolina United States 29588
    129 Investigational Site Rapid City South Dakota United States 57702
    130 Investigational Site Jackson Tennessee United States 38305
    131 Investigational Site Allen Texas United States 75013
    132 Investigational Site Austin Texas United States 78731
    133 Investigational Site Dallas Texas United States 75203
    134 Investigational Site Dallas Texas United States 75218
    135 Investigational Site Dallas Texas United States 75231
    136 Investigational Site Dallas Texas United States 75251
    137 Investigational Site Houston Texas United States 77062
    138 Investigational Site Houston Texas United States 77065
    139 Investigational Site Houston Texas United States 77074
    140 Investigational Site Houston Texas United States 77098
    141 Investigational Site McKinney Texas United States 75070
    142 Investigational Site North Richland Hills Texas United States 76180
    143 Investigational Site Tomball Texas United States 77375
    144 Investigational Site Orem Utah United States 84058
    145 Investigational Site Salt Lake City Utah United States 84102
    146 Investigational Site Salt Lake City Utah United States 84124
    147 Investigational Site Danville Virginia United States 24541
    148 Investigational Site Midlothian Virginia United States 23114
    149 Investigational Site Richmond Virginia United States 23220
    150 Investigational Site Bothell Washington United States 98011

    Sponsors and Collaborators

    • Purdue Pharma LP

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Purdue Pharma LP
    ClinicalTrials.gov Identifier:
    NCT01427283
    Other Study ID Numbers:
    • ONU3705
    • 2011-005061-20
    First Posted:
    Sep 1, 2011
    Last Update Posted:
    Feb 12, 2015
    Last Verified:
    Feb 1, 2015

    Study Results

    No Results Posted as of Feb 12, 2015